A UK Parliamentary debate on 18 May saw crossparty calls to conduct an urgent review of the evidence for psilocybin’s current status as a Schedule 1...
The Royal College of Psychiatrists, Heroic Hearts and other leading mental health charities have written letters to the Veterans Minister and the Minister of State for...
For the next two weeks, a digital poster campaign will be featured in London asking the UK public “Could magic mushrooms be medicine?”.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn Life Sciences an Innovation Passport for its proprietary ketamine-assisted therapy for the treatment of...
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
UK-based global nootropics company Puresport has had its Reishi, Cordyceps and Lion’s Mane supplements certified by Informed Sport, the gold-standard independent certification body.
Breaking Convention’s 11th conference, Worlds Collide, will feature themed panel discussions, art exhibitions and stalls.
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...